(Q48476825)

11 February 2018

title

Primary breast cancer phenotypes associated with propensity for central nervous system metastases. (English)

1 reference

11 February 2018

1 reference

Yee-Lu Tham

1

1 reference

11 February 2018

Krystal Sexton

2

1 reference

11 February 2018

Rita Kramer

3

1 reference

11 February 2018

Susan Hilsenbeck

4

1 reference

11 February 2018

Richard Elledge

5

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 August 2006

1 reference

11 February 2018

published in

Cancer

1 reference

11 February 2018

volume

107

1 reference

11 February 2018

page(s)

696-704

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

Brain metastases from breast cancer: identification of a high-risk group

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

The natural history of breast cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Brain metastases in breast cancer patients receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Breast carcinoma: Pattern of metastasis at autopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Central nervous system metastasis from breast carcinoma. Autopsy study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Central nervous system metastases in women after multimodality therapy for high risk breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Estrogen receptor: A prognostic factor in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Seven cases of breast cancer recurrence limited to the central nervous system without other visceral metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

CNS metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Brain metastases in breast cancer; natural history, prognostic factors and outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Patterns of metastatic breast cancer in relation to histological type.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Prognostic and predictive value of p53 and p21 in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Clinical studies of Bcl-2 and treatment benefit in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22041

7 January 2021

Identifiers

DOI

10.1002/CNCR.22041

1 reference

11 February 2018

PubMed ID

16826579

1 reference

11 February 2018